MedinCell (MEDCL) Aandelenoverzicht
MedinCell S.A., een farmaceutisch bedrijf, ontwikkelt langwerkende injectables in verschillende therapeutische gebieden in Frankrijk. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 6/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
MEDCL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
MedinCell S.A. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €27.10 |
| 52 Week Hoogtepunt | €39.68 |
| 52 Week Laag | €15.42 |
| Bèta | 1.0 |
| 1 maand verandering | 2.03% |
| 3 maanden verandering | 16.71% |
| 1 Jaar Verandering | 68.95% |
| 3 jaar verandering | 343.54% |
| 5 jaar verandering | 203.13% |
| Verandering sinds IPO | 268.71% |
Recent nieuws en updates
Narratiefupdate • Jul 03
MEDCL: Fair Outlook Balances Regulatory Milestone Prospects With Execution And Funding Risks
Analysts have raised their fair value estimate for MedinCell to €30.00 from €27.00, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together support a higher price target despite more tempered profitability expectations. Analyst Commentary Analysts covering MedinCell are using a wider range of scenarios in their models, reflecting both the potential of the company’s pipeline and the execution risks that come with it.
Narratiefupdate • Jun 19
MEDCL: Long Acting Schizophrenia Injection Pipeline Will Drive Future Share Price Upside
Analysts have nudged their price target for MedinCell slightly higher, from €34.76 to about €35.07. This reflects updated assumptions on fair value, growth, margins, and future P/E, in line with recent upward revisions seen across other covered stocks.Analyseartikel • Jun 17
MedinCell (ENXTPA:MEDCL) Stock Could Be 29.1% Undervalued After UZEDY And Pipeline Progress
Recent updates around MedinCell (ENXTPA:MEDCL) focus on stronger royalty income from UZEDY, progress on its Olanzapine long acting injectable toward a late 2026 US launch, and higher R&D spending that keeps the company in a loss-making phase. See our latest analysis for MedinCell. MedinCell's share price has recently given back some gains, with a 1 day share price return of 12.06% down and a 7 day share price return of 7.23% down. This is despite the 90 day share price return being 20.43% up...Narratiefupdate • Jun 04
MEDCL: Long Acting Schizophrenia Injection Progress Will Support Future Upside
Analysts have adjusted their fair value estimate for MedinCell slightly higher, from €34.28 to €34.76. They cite updated assumptions on discount rates, long term profit margins and future P/E levels as the basis for this revision.Recent updates
Narratiefupdate • Jul 03
MEDCL: Fair Outlook Balances Regulatory Milestone Prospects With Execution And Funding Risks
Analysts have raised their fair value estimate for MedinCell to €30.00 from €27.00, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which together support a higher price target despite more tempered profitability expectations. Analyst Commentary Analysts covering MedinCell are using a wider range of scenarios in their models, reflecting both the potential of the company’s pipeline and the execution risks that come with it.Narratiefupdate • Jun 19
MEDCL: Long Acting Schizophrenia Injection Pipeline Will Drive Future Share Price Upside
Analysts have nudged their price target for MedinCell slightly higher, from €34.76 to about €35.07. This reflects updated assumptions on fair value, growth, margins, and future P/E, in line with recent upward revisions seen across other covered stocks.Analyseartikel • Jun 17
MedinCell (ENXTPA:MEDCL) Stock Could Be 29.1% Undervalued After UZEDY And Pipeline Progress
Recent updates around MedinCell (ENXTPA:MEDCL) focus on stronger royalty income from UZEDY, progress on its Olanzapine long acting injectable toward a late 2026 US launch, and higher R&D spending that keeps the company in a loss-making phase. See our latest analysis for MedinCell. MedinCell's share price has recently given back some gains, with a 1 day share price return of 12.06% down and a 7 day share price return of 7.23% down. This is despite the 90 day share price return being 20.43% up...Narratiefupdate • Jun 04
MEDCL: Long Acting Schizophrenia Injection Progress Will Support Future Upside
Analysts have adjusted their fair value estimate for MedinCell slightly higher, from €34.28 to €34.76. They cite updated assumptions on discount rates, long term profit margins and future P/E levels as the basis for this revision.Narratiefupdate • Apr 27
MEDCL: Long-Acting Schizophrenia Injection Progress Will Drive Future Upside
The analyst price target for MedinCell has increased slightly from €33.85 to €34.28 as analysts adjust their assumptions for revenue growth, profit margins and future P/E expectations. What's in the News MedinCell and Teva Pharmaceuticals reported that the U.S. FDA accepted the New Drug Application for TEV-'749, an investigational once monthly olanzapine extended release injectable suspension for adults with schizophrenia, using MedinCell's SteadyTeq copolymer technology (Key Developments).Narratiefupdate • Apr 10
MEDCL: Schizophrenia Injection And 2026 Sales Outlook Will Drive Upside
Narrative Update on MedinCell The analyst price target for MedinCell remains steady at €33.85, as analysts keep their fair value view, discount rate, revenue growth outlook and profit margin assumptions essentially unchanged. What's in the News MedinCell completed a follow on equity offering of 2,370,000 ordinary shares, raising €48.2295 million at a price of €20.35 per share, via a subsequent direct listing (Key Developments).Narratiefupdate • Mar 27
MEDCL: 2026 Revenue Ramp And Schizophrenia Launch Will Drive Upside
Analysts now set their price target for MedinCell at €33.85, slightly below the prior €34.23. This reflects updated assumptions on long term profit margins and a higher future P/E multiple in their models.Narratiefupdate • Mar 11
MEDCL: 2026 Sales Outlook And New Schizophrenia Therapy Will Drive Upside
Analysts have trimmed their price target on MedinCell by about €1.04 to reflect an updated fair value of €34.23, as they factor in revised assumptions around revenue growth, profit margins and future P/E expectations. What's in the News MedinCell completed a follow on equity offering of ordinary shares, raising about €48.23 million by issuing 2,370,000 shares at €20.35 per share, via a subsequent direct listing (Key Developments).Narratiefupdate • Feb 25
MEDCL: 2026 Revenue Outlook And New Schizophrenia Drug Will Support Upside
Analysts have kept their price target for MedinCell steady at €35.26, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What's in the News Teva Pharmaceuticals and MedinCell announced that the U.S. FDA has accepted the New Drug Application for TEV-'749, an olanzapine extended-release injectable suspension for adult schizophrenia treatment, using MedinCell’s SteadyTeq copolymer technology for controlled sustained drug release (Key Developments).Narratiefupdate • Feb 09
MEDCL: 2026 Revenue Guidance Will Support Upside As Profitability Outlook Strengthens
Analysts have trimmed their price target on MedinCell to about €35.26 from roughly €36.16, citing slightly higher discount rate assumptions, modestly softer revenue growth expectations of around 61.5% and a lower projected profit margin of about 70.3%, partly offset by a higher assumed future P/E multiple near 14.5x. What's in the News MedinCell issued revenue guidance for 2026, with expected net sales in a range of $250 million to $280 million.Narratiefupdate • Jan 25
MEDCL: Index Inclusion Will Support Upside As Profitability Outlook Strengthens
Analysts have raised their price target on MedinCell to €36.16 from €35.10, citing updated assumptions that incorporate a higher projected profit margin along with a lower future P/E multiple in their models. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which covers liquid small-cap companies across 23 developed markets, increasing its visibility to global equity investors who track MSCI benchmarks (Key Developments).Narratiefupdate • Jan 11
MEDCL: Index Inclusion Will Support Future Upside Potential
Analysts have raised their price target on MedinCell to €35.10. The latest update reflects adjusted expectations around revenue growth, profit margins and future P/E assumptions.Narratiefupdate • Dec 19
MEDCL: Index Inclusion And New FDA Label Will Drive Upside Potential
Analysts have marginally raised their price target on MedinCell from €34.39 to €35.10, citing slightly stronger long term revenue growth expectations that more than offset a modestly lower projected profit margin and a reduced future P E multiple. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, increasing its visibility among global institutional and index-tracking investors from 24 November 2025 (company announcement).Narratiefupdate • Dec 05
MEDCL: Future Index Inclusion Will Drive Visibility And Earnings Upside Potential
Analysts have modestly reduced their price target for MedinCell by approximately $0.49 per share, reflecting tempered expectations for revenue growth, partially offset by improved projected profit margins and slightly lower future valuation multiples. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, boosting its visibility among global institutional investors and index-tracking funds, effective at the opening of trading on 24 November 2025 (Client Announcement) The FDA has approved UZEDY, a once monthly, subcutaneous long acting risperidone injection using MedinCell’s SteadyTeq technology, for maintenance treatment of bipolar I disorder in adults, expanding its label beyond schizophrenia (Product Related Announcement) MedinCell plans to submit a New Drug Application in the US for Olanzapine LAI, a once monthly long acting injection for schizophrenia using its co polymer technology licensed to Teva, in the fourth quarter of 2025, following positive Phase 3 safety data (Product Related Announcement) UZEDY has received regulatory approval in South Korea and is showing strong commercial traction, with 2024 net sales of 117 million dollars and 95 million dollars already in the first half of 2025.Analyseartikel • Dec 01
MedinCell S.A.'s (EPA:MEDCL) 27% Cheaper Price Remains In Tune With Revenues
MedinCell S.A. ( EPA:MEDCL ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...Narratiefupdate • Nov 21
MEDCL: Index Inclusion Will Drive Increased Visibility And Market Confidence
Analysts have slightly reduced their fair value price target for MedinCell from $35.16 to $34.87, reflecting tempered expectations around revenue growth and profit margins. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which may enhance visibility among institutional investors and index-tracking funds.Narratiefupdate • Nov 06
MEDCL: Profit Margins Are Expected To Improve Significantly With Recent FDA Approval
Analysts have raised their price target for MedinCell from $31.16 to $35.16. This change reflects increased confidence in the company’s future profitability and outlook, even though there is a slightly higher discount rate and moderated revenue growth projections.Narratiefupdate • Oct 23
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
Analysts have raised their price target for MedinCell from €26.90 to €31.16, citing improved revenue growth projections and favorable updates to future earnings expectations as key drivers for this upward revision. What's in the News FDA approves UZEDY, a once-monthly, long-acting risperidone injection, as monotherapy or adjunctive therapy for maintenance treatment of bipolar I disorder in adults.Narratiefupdate • Oct 09
Global Expansion And Extended Patents Will Unlock Future Opportunities
Analysts have raised their price target for MedinCell from $24.47 to $26.90, citing stronger fair value projections and underlying optimism in the company’s financial outlook. What's in the News MedinCell plans to submit a New Drug Application (NDA) for Olanzapine LAI, a once-monthly long-acting treatment for schizophrenia, in the US during the fourth quarter of 2025 (Key Developments).Narratiefupdate • Sep 25
Global Expansion And Extended Patents Will Unlock Future Opportunities
The upward revision in MedinCell's price target reflects a significant increase in consensus revenue growth forecasts coupled with a notable decline in the future P/E ratio, resulting in a new fair value estimate of €24.47. What's in the News UZEDY, a long-acting injectable risperidone for schizophrenia, received regulatory approval in South Korea and will be distributed by Teva Handok.Analyseartikel • Sep 25
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 30...Nieuw narratief • Sep 05
Global Expansion And Extended Patents Will Unlock Future Opportunities
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.Analyseartikel • Jun 19
News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...Analyseartikel • Dec 25
Industry Analysts Just Made An Incredible Upgrade To Their MedinCell S.A. (EPA:MEDCL) Revenue Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...Analyseartikel • Jul 05
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
The latest analyst coverage could presage a bad day for MedinCell S.A. ( EPA:MEDCL ), with the analysts making...Analyseartikel • Apr 26
Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Despite an already strong run, MedinCell S.A. ( EPA:MEDCL ) shares have been powering on, with a gain of 30% in the...Analyseartikel • Jan 09
Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 26...Analyseartikel • Mar 02
The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
MedinCell S.A. ( EPA:MEDCL ) shareholders might be concerned after seeing the share price drop 17% in the last month...Rendement voor aandeelhouders
| MEDCL | FR Pharmaceuticals | FR Markt | |
|---|---|---|---|
| 7D | -8.2% | 1.1% | -1.6% |
| 1Y | 69.0% | -4.0% | 0.8% |
Rendement versus industrie: MEDCL overtrof de French Pharmaceuticals industrie, die het afgelopen jaar een rendement -4 % opleverde.
Rendement versus markt: MEDCL overtrof de French markt, die het afgelopen jaar een rendement opleverde van 0.8 %.
Prijsvolatiliteit
| MEDCL volatility | |
|---|---|
| MEDCL Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in FR Market | 10.8% |
| 10% least volatile stocks in FR Market | 2.5% |
Stabiele aandelenkoers: De aandelenkoers van MEDCL is de afgelopen 3 maanden volatiel geweest in vergelijking met de French markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van MEDCL is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen French.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2003 | 140 | Christophe Douat | www.medincell.com |
MedinCell S.A., een farmaceutisch bedrijf, ontwikkelt langwerkende injectables in verschillende therapeutische gebieden in Frankrijk. Het ontwikkelt oplossingen op basis van BEPO, een langwerkende injecteerbare technologie, en biedt UZEDY (mdc-IRM) voor de behandeling van schizofrenie bij volwassenen. De producten van het bedrijf in ontwikkeling omvatten mdc-CWM, een formulering met verlengde afgifte van celecoxib in Fase III-onderzoek voor gebruik bij de behandeling van postoperatieve pijn en ontsteking; en mdc-TJK, een subcutane injectie die in Fase III van klinisch onderzoek is voor gebruik bij de behandeling van schizofrenie.
MedinCell S.A. Samenvatting
| MEDCL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | €973.00m |
| Inkomsten(TTM) | -€31.29m |
| Inkomsten(TTM) | €24.28m |
40.1x
P/S-verhouding-31.1x
Koers/WinstverhoudingIs MEDCL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MEDCL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €24.28m |
| Kosten van inkomsten | €0 |
| Brutowinst | €24.28m |
| Overige uitgaven | €55.56m |
| Inkomsten | -€31.29m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Dec 08, 2026
| Winst per aandeel (EPS) | -0.87 |
| Brutomarge | 100.00% |
| Nettowinstmarge | -128.88% |
| Schuld/Eigen Vermogen Verhouding | 1,795.9% |
Hoe presteerde MEDCL op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/10 01:38 |
| Aandelenkoers aan het einde van de dag | 2026/07/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
MedinCell S.A. wordt gevolgd door 12 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Seynnaeve | Degroof Petercam |
| Michael DiFiore | Evercore ISI |
| Raghuram Selvaraju | H.C. Wainwright & Co. |